Diseases of immune dysregulation: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 61: | Line 61: | ||
{{familytree | | | | | | | | | | | |`| K01 | | | | | | | | | | | |K01=Prolidase deficiency. PEPD, AR }} | {{familytree | | | | | | | | | | | |`| K01 | | | | | | | | | | | |K01=Prolidase deficiency. PEPD, AR }} | ||
{{familytree/end}} | {{familytree/end}} | ||
==Chediak Higashi Syndrome== | |||
* | |||
* | |||
* | |||
For more information on Chediak Higashi syndrome, [[Chediak Higashi syndrome|click here]]. | |||
==Griscelli Syndrome type 2== | |||
* | |||
* | |||
* |
Revision as of 19:18, 10 October 2018
Immunodeficiency Main Page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Template:Zahir, Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
Classification
Diseases of Immune Dysregulation | |||||||||||||||||||||||||
(A) Hemophagocytic lymphohistiocytosis (HLH) & EBV susceptibility | (B) Syndromes with Autoimmunity and Others | ||||||||||||||||||||||||
Hemophagocytic Lymphohistiocytosis (HLH) & EBV Susceptibility
Diseases Of Immune Dysregulation: (A) Hemophagocytic Lymphohistiocytosis (HLH) & EBV Susceptibility | |||||||||||||||||||||||||||||||||||||||||||||
Hemophagocytic Lymphohistiocytosis(HLH) | Susceptibility to EBV | ||||||||||||||||||||||||||||||||||||||||||||
Hypopigmentation | Familial Hemophagocytic Lymphohistiocytosis Syndromes | EBV Associated with HLH | |||||||||||||||||||||||||||||||||||||||||||
Chediak Higashi Syndrome:LYST | Perforin Deficiency(FHL2) | RASGRP1 Deficiency | XL,XLP1.SH2DIA | ||||||||||||||||||||||||||||||||||||||||||
Griscelli Syndrome type2:RAB27a | UNCBD/Munc13-4 deficiency(FHL3) | CD70 Deficiency | XL,XLP2,XIAP | ||||||||||||||||||||||||||||||||||||||||||
Hermansky Pudlak Syndrome type2:AP3B1 | Syntaxin II Deficiency(FHL4) | CTPS1 Deficiency | AR, CD27 Deficiency | ||||||||||||||||||||||||||||||||||||||||||
Hermansky Pudlak Syndrome type10 | STXBP2/Munc18-2 Deficiency | RLTPR (CARMIL2) Deficiency | FAAP24 Deficiency | ||||||||||||||||||||||||||||||||||||||||||
ITK Deficiency | |||||||||||||||||||||||||||||||||||||||||||||
MAGT1 Deficiency | |||||||||||||||||||||||||||||||||||||||||||||
PRKCD Deficiency | |||||||||||||||||||||||||||||||||||||||||||||
Syndromes with Autoimmunity and Others
Diseases of Immune Dysregulation: (B) Syndromes with Autoimmunity and Others | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Syndromes with Autoimmunity | Immune Dysregulation with Colitis: IBD, Normal Tc & Bc | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Increased CD4-CD8-TCR alpha/beta (Double Negative T cells) | IL10 Deficiency, IL10, AR | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | Occassionally | NO: Regulatory T cells Defects? | IL10Ra Deficiency, IL10RA, AR | ||||||||||||||||||||||||||||||||||||||||||||||||||
ALPS, Autoimmune Lymphoproliferative Syndrome | LRBA Deficiency | NO | YES | IL10Rb Deficiency, IL10RB, RA | |||||||||||||||||||||||||||||||||||||||||||||||||
ALPS-FAS TNFRSF, AD or AR | STAT3 GOF mutation,STAT3 AD | Autoimmune Polyendocrinopathy with candidiasis & ectodermal dystrophy: APECED (APS-1) | IPEX Immune dysregulation, Polyendocrinopathy,enteropathy,X-linked FOXP-3 | NFATS haploinsufficiency, NAFTS, AD | |||||||||||||||||||||||||||||||||||||||||||||||||
ALPS-FASLG TNFSF6, AR | ITCH Deficiency, ITCH, AR | CD25 Deficiency, IL2RA, AR | |||||||||||||||||||||||||||||||||||||||||||||||||||
ALPS-Caspase10, Casp10, AD | ZAP70 combined hylomorphic and activation mutations, ZAP70, AR | CTLA4 deficiency (ALPSV) CTLA4, AD | |||||||||||||||||||||||||||||||||||||||||||||||||||
ALPS-Caspase8, Casp8, AR | Tripeptidyl-peptidase II deficiency, TPP2, AR | BACH2 deficiency. BACH2, AD | |||||||||||||||||||||||||||||||||||||||||||||||||||
FADD deficiency, FADD, AR | JAK1 GOF, JAK1, AD | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Prolidase deficiency. PEPD, AR | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Chediak Higashi Syndrome
For more information on Chediak Higashi syndrome, click here.